[Molecular mechanize and clinical feature of azole-resistant Candida albicans strains and new strategy of treatment].
Maesaki
S
S
D000818:Animals; D000935:Antifungal Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001393:Azoles / Q000494:pharmacology* / Q000627:therapeutic use; D002176:Candida albicans / Q000187:drug effects*; D002177:Candidiasis / Q000150:complications / Q000188:drug therapy*; D004352:Drug Resistance, Microbial / Q000235:genetics; D004359:Drug Therapy, Combination; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D009894:Opportunistic Infections / Q000150:complications / Q000188:drug therapy; D016559:Tacrolimus / Q000627:therapeutic use
D000935:Antifungal Agents; D001393:Azoles; D007166:Immunosuppressive Agents; D016559:Tacrolimus